Meningococcal Vaccines: MenACWY, MenB, and Travel Vaccines

1. Why Meningococcal Vaccines Are Exceptional
2. Quadrivalent Conjugate Vaccines — MenACWY
3. US Routine Schedule for MenACWY
4. MenB Vaccines — the Latest Advance
5. Why Serogroup B Was So Hard to Vaccinate Against
6. MenAfriVac — a Public Health Triumph for Africa
7. Hajj Vaccination
8. High-Risk Groups Needing All Meningococcal Vaccines
9. Vaccine Waning and Booster Strategy
10. Key Research Papers
11. Connections
12. Featured Videos

Why Meningococcal Vaccines Are Exceptional

Among all vaccines, the story of meningococcal vaccination stands out as one of the most dramatic public health successes of the past 30 years. These vaccines do not just reduce disease — in the populations where they have been deployed comprehensively, they have essentially eliminated specific serogroups of meningococcal disease almost entirely.

Before 1999, serogroup C meningococcal disease killed approximately 150 young people per year in England alone. Many more were left with permanent disabilities — deafness, brain damage, amputated limbs. Parents lived in dread of the disease, particularly in the autumn and winter when outbreaks occurred. The UK launched a mass meningococcal C conjugate vaccination campaign in 1999–2000 targeting all children and teenagers. Within two years, serogroup C disease fell by more than 95%. The annual death toll from serogroup C meningococcal disease in England dropped from 150 to fewer than 5. This is what an effective vaccine can achieve.

MenAfriVac, deployed across the African meningitis belt from 2010, achieved something equally remarkable — reducing serogroup A disease from epidemic proportions (with periodic outbreaks affecting hundreds of thousands) to near-zero in vaccinated populations. These are genuine victories. Understanding the full range of meningococcal vaccines available helps families and clinicians ensure that everyone at risk is protected.

Back to Table of Contents

Quadrivalent Conjugate Vaccines — MenACWY

The quadrivalent MenACWY vaccines cover four of the five most important meningococcal serogroups: A, C, W, and Y. They are called "conjugate" vaccines because the polysaccharide antigen (the sugar coating on the outside of the bacterium) is chemically linked — conjugated — to a protein carrier. This conjugation is what makes these vaccines so effective and so durable compared to older polysaccharide-only vaccines.

Without conjugation, the immune system treats the polysaccharide as a T-cell-independent antigen — it produces some antibody but no immune memory. Protection lasts only 3–5 years and infants under 2 years generate minimal response. With conjugation to a carrier protein, the polysaccharide becomes a T-cell-dependent antigen. The immune system creates memory B cells, the response is stronger and more durable, and infants can be protected from early in life.

Three MenACWY conjugate vaccines are licensed in the United States:

• Menactra (MenACWY-D): Polysaccharide conjugated to diphtheria toxoid. Licensed for ages 9 months to 55 years.
• Menveo (MenACWY-CRM): Conjugated to CRM197, a non-toxic variant of diphtheria toxin. Licensed from 2 months of age.
• MenQuadfi (MenACWY-TT): Conjugated to tetanus toxoid. Licensed from 2 years of age.

All three are highly effective at preventing serogroup A, C, W, and Y meningococcal disease and at reducing nasopharyngeal carriage, which means vaccination of adolescents also provides some herd protection to unvaccinated contacts.

Back to Table of Contents

US Routine Schedule for MenACWY

The US Advisory Committee on Immunization Practices (ACIP) recommends the following routine schedule for MenACWY vaccination:

• First dose at age 11–12 years: Given alongside HPV and Tdap vaccines at the pre-teen visit. This is the foundation of meningococcal protection in the US.
• Booster at age 16 years: This booster is critically important. Protection from the 11–12 year dose wanes significantly over the following 3–5 years. The highest-risk period for meningococcal disease in young people is the college years (17–22 years), particularly for those living in dormitories where close contact is common. A student who was vaccinated at 11 and did not receive a booster at 16 may have minimal protection when starting college at 18.
• High-risk infants and toddlers: Children with complement deficiency, anatomical or functional asplenia, or HIV infection should receive a primary series starting at 2 months, with doses at 2, 4, 6, and 12 months (using Menveo or Menactra depending on age and product licensing).
• Adults aged 21 or under at college: Those who did not receive a booster at 16 should receive one before starting college.

Students living in dormitories have a higher risk of meningococcal disease because dormitory settings facilitate close contact, shared meals, late nights with impaired immunity, and potential exposure to new strains brought by students from different regions. Many colleges now require proof of meningococcal vaccination for dorm residency.

Back to Table of Contents

MenB Vaccines — the Latest Advance

Serogroup B was the last major meningococcal serogroup to be effectively tackled by vaccination, and it took a fundamentally different scientific approach to do it. Two MenB vaccines are now licensed in the United States:

• Bexsero (4CMenB, GSK): Contains four recombinant surface proteins plus outer membrane vesicles from a New Zealand epidemic strain. Two-dose primary series, 1 month apart, for adolescents and adults.
• Trumenba (MenB-FHbp, Pfizer): Contains two variants of factor H binding protein (fHbp), a key meningococcal surface protein. Can be given as a two-dose or three-dose series depending on the schedule used.

MenB vaccines are not yet part of the universal routine schedule for all adolescents in the US, primarily due to cost-effectiveness modeling. However, ACIP recommends MenB vaccination for:

• Individuals with complement component deficiencies (C5–C9, properdin, factor D)
• Individuals with anatomical or functional asplenia
• Microbiologists routinely exposed to N. meningitidis isolates
• People identified at increased risk during an outbreak attributable to serogroup B

For adolescents and young adults aged 16–23, ACIP recommends shared clinical decision-making — meaning the vaccine is recommended but the decision is made in conversation between patient and clinician based on individual risk preferences. College outbreaks (such as those at Princeton in 2013–2014 and UC Santa Barbara in 2013) have demonstrated that serogroup B can cause explosive campus epidemics, which drove emergency authorization of Bexsero in the US before its formal licensure.

Back to Table of Contents

Why Serogroup B Was So Hard to Vaccinate Against

The scientific challenge of making a MenB vaccine is one of the most fascinating stories in modern vaccinology. For serogroups A, C, W, and Y, the approach was relatively straightforward — use the polysaccharide capsule as the antigen and conjugate it to a carrier protein. But this approach fails completely for serogroup B.

The reason is molecular mimicry. The capsular polysaccharide of serogroup B — polysialic acid — is chemically almost identical to polysialic acid decorating human neural cell adhesion molecules (NCAM). The immune system, which is exquisitely trained not to attack "self" antigens, is therefore tolerant to the serogroup B capsule. Injecting it as a vaccine produces minimal antibody response, and even if it did, those antibodies might attack the human nervous system.

The solution was to bypass the capsule entirely and use other surface proteins as antigens — proteins that are present on the bacterium but not on human cells. Two approaches have worked:

• Outer membrane vesicle (OMV) approach: Blisters of the outer membrane shed naturally by the bacterium contain surface proteins that can stimulate immunity. The New Zealand epidemic was controlled in the mid-2000s using a tailored OMV vaccine. Bexsero incorporates an OMV component alongside recombinant proteins to broaden coverage.
• Reverse vaccinology: Scientists at GSK sequenced the entire genome of N. meningitidis serogroup B and systematically screened every predicted surface protein for its ability to generate bactericidal antibodies. This approach — reverse vaccinology — was pioneered specifically for MenB and identified the key proteins used in Bexsero and Trumenba. It is now a standard tool in vaccine development globally.

Back to Table of Contents

MenAfriVac — a Public Health Triumph for Africa

The African meningitis belt — a band of countries across sub-Saharan Africa from Senegal in the west to Ethiopia in the east — had been devastated by periodic epidemics of serogroup A meningococcal disease for over a century. During epidemic years, attack rates could reach 1 in 100 people in affected communities. The death toll from a single season could reach tens of thousands. Between epidemics, endemic disease caused thousands more deaths annually.

MenAfriVac (PsA-TT) was developed specifically for this setting through the Meningitis Vaccine Project, a partnership between PATH, WHO, and the Bill & Melinda Gates Foundation. The goal was to create a vaccine that could be produced and delivered at a cost of USD $0.40 per dose — a price point that made large-scale deployment in Africa feasible. The vaccine uses a meningococcal A polysaccharide conjugated to tetanus toxoid, manufactured in India by the Serum Institute.

Mass vaccination campaigns began in 2010 in Burkina Faso, Mali, and Niger, and expanded across the belt in subsequent years. The results were remarkable:

• Serogroup A meningococcal disease — previously the dominant cause of epidemic meningitis in Africa — virtually disappeared in vaccinated populations.
• Epidemic A disease fell by more than 99% in countries that completed their campaigns.
• Carriage of serogroup A in the nasopharynx fell dramatically, suggesting herd immunity was reducing transmission even in unvaccinated individuals.

MenAfriVac stands as one of the most cost-effective public health interventions ever deployed. It demonstrates what is possible when vaccine development is explicitly designed around the needs and economic realities of the populations who will benefit most.

Back to Table of Contents

Hajj Vaccination

The annual Hajj pilgrimage to Mecca gathers over 2 million Muslims from around the world in extremely close proximity for several days. This gathering has historically been associated with outbreaks of meningococcal disease. In 2000–2001, a major outbreak of serogroup W meningococcal disease occurred among Hajj pilgrims and spread globally when pilgrims returned home, killing people in multiple countries including the UK and France.

This Hajj-associated outbreak was historically important for two reasons. First, it demonstrated how rapidly a new meningococcal serogroup could spread internationally in an era of mass air travel. Second, it accelerated the development and licensure of quadrivalent vaccines — before this outbreak, the main concern in many countries was serogroup C, and bivalent (AC) vaccines were standard. The serogroup W outbreak pushed manufacturers to develop the quadrivalent ACWY products that are now used worldwide.

Saudi Arabia now requires all Hajj and Umrah pilgrims to present proof of valid quadrivalent meningococcal vaccination as part of their visa application. The specific requirement:

• Quadrivalent meningococcal polysaccharide or conjugate vaccine
• Given within 3 years of travel (some years specify 5 years for conjugate vaccines)
• At least 10 days before arrival in Saudi Arabia

Hajj pilgrims from the UK must show a vaccination certificate issued by an authorised yellow fever vaccination centre. For UK residents, the MenACWY vaccine is available free on the NHS for eligible Hajj and Umrah pilgrims. Pilgrims should plan vaccination at least 2–3 weeks before departure to allow full immune response to develop.

Back to Table of Contents

High-Risk Groups Needing All Meningococcal Vaccines

Certain individuals face profoundly elevated risk of meningococcal disease and require both MenACWY and MenB vaccination, plus ongoing boosters. These high-risk groups include:

• Complement-deficient individuals: The complement system is the body's primary mechanism for killing gram-negative bacteria like N. meningitidis. People with inherited deficiencies of terminal complement components (C5, C6, C7, C8, or C9), or of properdin or factor D (which activate the alternative complement pathway), cannot form the membrane attack complex that punches holes in bacterial membranes. Their risk of meningococcal disease is estimated to be 1,000 to 10,000 times higher than the general population. They need both MenACWY and MenB vaccines, and boosters every 3–5 years throughout life.
• Asplenic individuals: The spleen filters encapsulated bacteria from the bloodstream and coordinates early antibody responses. People without a functioning spleen — whether from surgical removal (after trauma or haematological disease), infarction (as in sickle cell disease), or congenital absence — are at high risk of overwhelming infection with encapsulated organisms including N. meningitidis. They need MenACWY, MenB, and boosters every 3–5 years.
• HIV-infected individuals: HIV impairs the immune system's ability to respond to encapsulated bacteria. ACIP recommends MenACWY vaccination for all HIV-infected people aged 2 months and older, with a two-dose primary series and revaccination every 5 years.
• Eculizumab (Soliris) recipients: This drug, used for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome, blocks complement component C5 and creates iatrogenic terminal complement deficiency. Recipients have an extremely high risk of meningococcal disease and must be vaccinated before starting treatment and given antibiotic prophylaxis.
• Laboratory workers: Microbiologists who work routinely with N. meningitidis cultures should receive both MenACWY and MenB vaccines.

Back to Table of Contents

Vaccine Waning and Booster Strategy

Meningococcal vaccines — like many vaccines — do not provide lifelong protection after a single course. Understanding how immunity wanes is critical to designing effective vaccination schedules.

For MenACWY conjugate vaccines:

• Protection wanes substantially over 3–5 years, particularly in adolescents vaccinated at age 11–12. By age 16–17, antibody levels may have fallen below protective thresholds in a significant proportion of those vaccinated at 11–12.
• This is why the 16-year-old booster is not optional — it is essential for protection during the college years.
• High-risk individuals (complement deficiency, asplenia, HIV) require formal revaccination every 3–5 years throughout life, not just in adolescence.

For MenB vaccines:

• Post-marketing studies with Bexsero show antibody levels decline substantially in the year following vaccination.
• There is currently no established routine booster recommendation for MenB in the general adolescent population in the US, though this area is under active study.
• High-risk individuals who receive MenB should be revaccinated every 3–5 years based on the same logic applied to MenACWY.

The practical message for parents and patients: a child vaccinated at 11 is not protected for life. Check vaccination records, confirm the booster was given at 16, and ensure any high-risk individuals are receiving appropriate revaccination. When in doubt, a blood test (serum bactericidal antibody titer) can confirm whether protective antibody levels remain present.

Back to Table of Contents

Key Research Papers

1. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med. 2010;362(16):1511–1520. PMID 20410516
2. Maiden MCJ, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci USA. 1998;95(6):3140–3145. PMID 9501229
3. Pizza M, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science. 2000;287(5459):1816–1820. PMID 10710308
4. LaForce FM, et al. MenAfriVac: a triumph for public health and for Africa. Hum Vaccin Immunother. 2015;11(6):1484–1487. PMID 25875901
5. LaForce FM, et al. Epidemic meningitis due to group A Neisseria meningitidis in the African meningitis belt. Vaccine. 2009;27(Suppl 2):B13–B19. PMID 19477559
6. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis. 2010;50(Suppl 2):S54–S65. PMID 20067393
7. Cohn AC, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2013;62(RR-2):1–28. PMID 23445929
8. Harrison LH, et al. Risk factors for meningococcal disease in students in grades 9–12. J Infect Dis. 2008;197(9):1233–1238. PMID 18433326
9. Dretler AW, et al. Meningococcal vaccines: a review of clinical data for the physician. Curr Opin Infect Dis. 2021;34(3):259–265. PMID 33560696
10. MacNeil JR, et al. Use of MenACWY vaccines in persons aged ≥55 years for prevention of meningococcal disease: recommendations of ACIP. MMWR Morb Mortal Wkly Rep. 2020;69(10):277–281. PMID 32163382

Back to Table of Contents

Connections

• Treatment & Prevention Overview
• Antibiotic Treatment: Ceftriaxone and Dexamethasone
• Chemoprophylaxis and Resistance
• Symptoms & Diagnosis
• Neisseria Meningitidis Overview
• All Bacteria

Back to Table of Contents

Featured Videos